Crohn's disease and gastric sleeve surgery present a complex clinical intersection that requires careful, individualised assessment. Sleeve gastrectomy is one of the most commonly performed bariatric procedures in the UK, offering significant weight loss for people living with obesity. However, for those with Crohn's disease — a chronic inflammatory bowel condition affecting any part of the gastrointestinal tract — additional considerations around disease activity, nutritional status, medication, and surgical risk must be thoroughly evaluated before proceeding. This article outlines what patients and clinicians need to know about eligibility, risks, UK guidance, and post-operative management.

Can People with Crohn's Disease Have Gastric Sleeve Surgery?

People with Crohn's disease can be considered for gastric sleeve surgery, but eligibility depends on disease location, activity, nutritional status, and medications, requiring a full multidisciplinary assessment.

Have any more questions about this? Message our pharmaceutical team to get more info →

Sleeve gastrectomy, commonly known as gastric sleeve surgery, is one of the most frequently performed bariatric procedures in the UK. It involves removing approximately 75–80% of the stomach to create a narrow, sleeve-shaped pouch, which restricts food intake and promotes significant weight loss. For most patients with obesity, it is considered a safe and effective intervention. However, for individuals living with Crohn's disease — a chronic inflammatory bowel disease (IBD) affecting any part of the gastrointestinal tract — the decision is considerably more complex.

Crohn's disease does not automatically disqualify a person from having gastric sleeve surgery, but it introduces a range of clinical considerations that must be carefully evaluated. Unlike Roux-en-Y gastric bypass, which involves intestinal rerouting and carries a higher risk of nutritional complications in IBD patients, sleeve gastrectomy is often considered a more suitable bariatric option for those with Crohn's disease when surgery is deemed appropriate, largely because it does not alter intestinal continuity. However, the evidence base for this preference is largely observational and retrospective, and no formal UK guideline currently designates sleeve gastrectomy as the procedure of choice in IBD.

The decision to proceed must always be made on an individual basis. Factors such as disease location, current disease activity, nutritional status, and medication regimen all play a critical role in determining whether a patient is a suitable candidate. A multidisciplinary team (MDT) approach — involving a gastroenterologist, bariatric surgeon, dietitian, and specialist nurse — is essential before any surgical pathway is initiated.

How Crohn's Disease Affects Eligibility for Bariatric Surgery

Crohn's disease is not a contraindication under NICE CG189, but active disease, malnutrition, corticosteroid use, and prior bowel surgery can all affect a patient's suitability for bariatric surgery.

Eligibility for bariatric surgery in the UK is primarily guided by NICE Clinical Guideline CG189, which recommends consideration of surgery for adults with a BMI of 40 kg/m² or above, or between 35–40 kg/m² in the presence of significant obesity-related comorbidities. For adults with type 2 diabetes, NICE NG28 additionally supports consideration of metabolic surgery at a BMI of 30–34.9 kg/m², and lower thresholds may apply for people from some Black, Asian, and minority ethnic backgrounds. Crohn's disease itself is not listed as a contraindication, but it introduces several factors that can affect a patient's suitability.

In England, NHS bariatric surgery is commissioned as a Tier 4 (specialist surgical) service. Patients are typically required to complete a Tier 3 specialist weight management programme — involving dietetic, psychological, and medical input — before being considered for Tier 4 surgery. Access criteria and pathway timelines may vary by Integrated Care Board (ICB).

Key eligibility considerations include:

• Disease activity: Active Crohn's disease, particularly involving the upper gastrointestinal tract or stomach, significantly increases surgical risk. Elective bariatric surgery should be planned during a period of quiescent disease wherever possible, in line with BSG and ECCO peri-operative guidance. Any specific remission duration requirement should be agreed with the gastroenterology team on an individual basis.

• Nutritional status: Crohn's disease frequently causes malnutrition, anaemia, and deficiencies in iron, vitamin B12, vitamin D, and folate. These must be optimised prior to surgery to reduce perioperative risk.

• Immunosuppressive therapy: The strongest evidence for increased postoperative complications relates to systemic corticosteroids, which are associated with impaired wound healing and higher infection risk. Evidence regarding thiopurines (such as azathioprine) and biologic therapies (such as infliximab or adalimumab, which are administered by injection or infusion) is more limited and mixed; the timing and continuation of these agents around surgery should be planned individually in consultation with the gastroenterology team, in line with BSG and ECCO guidance.

• Previous bowel surgery: A history of intestinal resection may complicate the surgical approach and increase the risk of further nutritional deficiencies.

• Smoking: Smoking worsens Crohn's disease activity and impairs wound healing. Smoking cessation support should be offered as part of prehabilitation.

It is also worth noting that obesity may be associated with worse outcomes in some patients with Crohn's disease, and there is some evidence that excess adiposity can affect the pharmacokinetics of biologic therapies, though the clinical significance of this remains an area of ongoing research. In carefully selected patients, weight loss achieved through bariatric surgery may have a beneficial effect on overall health and potentially on disease management, though robust long-term evidence in this specific population remains limited.

Risks and Complications of Gastric Sleeve in Crohn's Disease

Patients with Crohn's disease face elevated risks including post-operative disease flare, impaired staple line healing, worsening nutritional deficiencies, and new or worsened gastro-oesophageal reflux disease.

All bariatric surgery carries inherent risks, but patients with Crohn's disease face an elevated and distinct risk profile that warrants thorough pre-operative counselling. Understanding these risks is essential for informed consent and shared decision-making.

General risks of gastric sleeve surgery include:

• Staple line leak

• Bleeding

• Gastro-oesophageal reflux disease (GORD), which may worsen or develop after sleeve gastrectomy

• Nutritional deficiencies

• Venous thromboembolism (VTE)

• Stricture or stenosis of the sleeve

• Gallstones (associated with rapid weight loss)

• Wound or intra-abdominal infection

• Sleeve dilation and potential weight regain over time

Crohn's disease-specific risks include:

• Post-operative disease flare: Surgical stress may trigger a flare of Crohn's disease in the weeks following surgery, though the precise mechanisms are not fully established.

• Impaired staple line healing: Chronic inflammation and, in particular, systemic corticosteroid use can delay healing and increase the risk of complications at the staple line.

• Worsening nutritional deficiencies: The reduced stomach volume limits dietary intake, compounding pre-existing malabsorption issues common in Crohn's disease.

• Drug absorption changes: Reduced gastric volume and altered gastric pH may affect the dissolution and absorption of certain oral medications. This is generally less pronounced after sleeve gastrectomy than after gastric bypass, but clinicians should review all oral formulations — including oral small-molecule agents used in IBD (such as JAK inhibitors), mesalazine, and azathioprine — in consultation with a pharmacist. Note that biologic therapies (such as infliximab and adalimumab) are administered by injection or infusion and are not affected by changes in gastric absorption. If you think a medicine may be causing side effects, report this via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

GORD is a particularly important consideration. Sleeve gastrectomy is associated with a higher incidence of new or worsened reflux compared to gastric bypass. In Crohn's patients who already have upper GI involvement or oesophageal symptoms, this risk requires careful pre-operative assessment, including upper GI endoscopy where indicated. If significant GORD or upper GI Crohn's disease is identified, an alternative bariatric procedure may be more appropriate. A proton pump inhibitor (PPI) is commonly prescribed in the early post-operative period per local protocol, and non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided where possible.

What UK Guidelines Say About Obesity Surgery and IBD

No dedicated NICE guideline addresses bariatric surgery in IBD; NICE CG189 provides the overarching framework, with BSG and ECCO guidance informing peri-operative management of Crohn's disease.

There is currently no dedicated NICE guideline specifically addressing bariatric surgery in patients with inflammatory bowel disease. NICE CG189 (Obesity: identification, assessment and management) provides the overarching framework for bariatric surgery referral in the UK but does not address IBD as a specific comorbidity in detail. NICE NG28 (Type 2 diabetes in adults: management) sets out additional metabolic surgery criteria for adults with type 2 diabetes. The British Obesity and Metabolic Surgery Society (BOMSS) and NHS England's commissioning policies acknowledge that complex comorbidities require individualised assessment, but explicit IBD-specific protocols remain limited.

The British Society of Gastroenterology (BSG) and European Crohn's and Colitis Organisation (ECCO) have published guidance on the management of Crohn's disease, including peri-operative considerations for patients undergoing abdominal surgery. Key recommendations relevant to bariatric surgery include:

• Optimising disease control prior to any elective procedure, with surgery planned during quiescent disease wherever possible

• Nutritional rehabilitation before surgery, including correction of micronutrient deficiencies

• Careful, individualised review of immunosuppressive therapy, with particular attention to systemic corticosteroids (which carry the strongest evidence for increased postoperative risk) and planned timing of biologic and immunomodulator therapy in consultation with the gastroenterology team

• Multidisciplinary involvement, ensuring gastroenterology input throughout the surgical pathway

BOMSS publishes standards for post-operative nutritional monitoring and guidance on medication management after bariatric surgery, which are relevant to all patients undergoing sleeve gastrectomy, including those with Crohn's disease.

In practice, NHS bariatric centres will typically require a formal gastroenterology opinion before listing a Crohn's patient for surgery. Some centres may decline to operate during periods of active disease or if the patient is on high-dose corticosteroids. Patients should be aware that access to bariatric surgery via the NHS is subject to Tier 3 completion and local ICB commissioning criteria, and that clinical complexity such as Crohn's disease may affect the pathway timeline.

Managing Crohn's Disease After Gastric Sleeve Surgery

Post-operative care requires close gastroenterology and bariatric collaboration, with priority given to nutritional monitoring, medication review, and ongoing disease surveillance using inflammatory markers and endoscopy.

Post-operative management of Crohn's disease following gastric sleeve surgery requires close collaboration between the bariatric and gastroenterology teams. The altered anatomy and reduced gastric capacity introduce new challenges in both disease monitoring and treatment.

Nutritional monitoring is a priority. Patients with Crohn's disease are already at elevated risk of deficiencies in:

• Iron and vitamin B12 (particularly if there is terminal ileal involvement)

• Vitamin D and calcium

• Folate, zinc, and magnesium

Post-sleeve gastrectomy, these risks are compounded by reduced dietary intake and potential changes in gastric acid secretion. Blood tests should be performed in line with BOMSS post-bariatric nutritional monitoring guidance. A typical schedule includes testing at three, six, and twelve months post-operatively, then annually, and should include as a minimum: full blood count (FBC), ferritin, vitamin B12, folate, vitamin D, calcium, parathyroid hormone (PTH), and liver function tests (LFTs), with zinc, copper, and selenium measured where clinically indicated. Supplementation should be adjusted based on results.

Standard post-sleeve supplementation, as recommended by BOMSS, typically includes a complete multivitamin and mineral supplement, calcium with vitamin D, and iron. Vitamin B12 supplementation should be considered, particularly in patients with terminal ileal Crohn's disease or prior ileal resection. Supplementation regimens should be reviewed and personalised by the dietitian and clinical team.

Medication management also requires review. Absorption issues after sleeve gastrectomy are generally less pronounced than after gastric bypass, but the reduced stomach size may still affect the dissolution of certain oral formulations. Enteric-coated or modified-release preparations (such as some forms of mesalazine) may be less reliably absorbed in some patients. Clinicians should review all oral medications in consultation with a pharmacist and consider switching to alternative formulations or routes of administration where necessary. Drug levels and clinical response should be monitored where available (for example, thiopurine metabolite levels). A PPI is commonly prescribed in the early post-operative period, and NSAIDs should be avoided where possible.

Disease monitoring should continue as per standard Crohn's disease protocols, including regular clinical review, inflammatory markers (CRP, faecal calprotectin), and endoscopic assessment as indicated. Patients should be advised to report any new or worsening gastrointestinal symptoms promptly, as these may represent a disease flare rather than expected post-operative changes. Smoking cessation support, psychological support, and ongoing dietetic follow-up are all important components of long-term care.

Talking to Your NHS Specialist Before Considering Weight Loss Surgery

Patients with Crohn's disease should discuss disease control, nutritional optimisation, and medication risks with their gastroenterologist and GP before pursuing an NHS bariatric surgery referral.

If you have Crohn's disease and are considering gastric sleeve surgery, the most important first step is an open and detailed conversation with your gastroenterologist and GP. Weight loss surgery is a significant intervention, and in the context of a chronic inflammatory condition, the decision requires careful, personalised assessment rather than a one-size-fits-all approach.

Questions worth raising with your specialist include:

• Is my Crohn's disease currently well-controlled enough to consider surgery?

• What nutritional assessments or optimisation do I need before being referred?

• How might my current medications affect surgical risk or recovery?

• Will my IBD medications need to be adjusted before or after surgery?

• Which type of bariatric surgery is most appropriate for my specific situation?

Your GP can refer you to an NHS Tier 3 specialist weight management service if you meet the NICE criteria for surgery. Tier 3 involves input from dietitians, psychologists, and specialist clinicians, and is a required step before Tier 4 (surgical) referral in most ICBs. Given the complexity of your medical history, it is likely that a joint clinic or MDT discussion involving both gastroenterology and bariatric surgery will be arranged before any decision is made. This is standard good practice and is in your best interest. Access criteria and waiting times may vary depending on your local ICB.

For further information, the NHS website provides patient-facing guidance on weight loss surgery, including risks, benefits, and what to expect from the NHS pathway.

Contact your GP or IBD nurse promptly if you experience:

• A flare of Crohn's symptoms whilst awaiting or recovering from surgery

• Significant unintentional weight loss or signs of malnutrition

• New or worsening reflux symptoms

• Concerns about medication absorption or effectiveness

Seek emergency care (call 999 or go to A&E) if you develop any of the following after surgery:

• Severe or worsening abdominal pain

• Fever, rapid heart rate, or feeling very unwell

• Persistent vomiting or inability to keep fluids down

• Vomiting blood or passing black, tarry stools

• Chest pain or shortness of breath

These symptoms may indicate a serious surgical complication and require urgent assessment.

Achieving a healthy weight can have real benefits for your overall health and potentially for your Crohn's disease management. With the right specialist support, many patients with IBD successfully navigate bariatric surgery and go on to achieve meaningful, sustained improvements in their quality of life.

Frequently Asked Questions